Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone in Acutely Psychotic Patients With Schizophrenia
NCT03465787Phase 3Completed
- Sponsor
- Bukwang Pharmaceutical
- Start
- Apr 2018
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lurasidone in schizophrenia, sponsored by Bukwang Pharmaceutical. Started Apr 2018; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03465787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03465787.